News | November 07, 2024
Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
US Generics grew 5% to Rs. 467 Crores for the quarter
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Subscribe To Our Newsletter & Stay Updated
